Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ulrika Andersson, Judith Schwartzbaum, Fredrik Wiklund, Sara Sjöström, Yanhong Liu, Spyros Tsavachidis, Anders Ahlbom, Anssi Auvinen, Helle Collatz-Laier, Maria Feychting, Christoffer Johansen, Anne Kiuru, Stefan Lönn, Minouk J. Schoemaker, Anthony J. Swerdlow, Roger Henriksson, Melissa Bondy & Beatrice Melin. (2010) A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncologica 49:6, pages 767-775.
Read now
Read now
Articles from other publishers (22)
S. Chemmalar, A. R. Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Loqman Mohamad Yusof, Mokrish Ajat, Kim Wei Chan & Md Zuki Abu Bakar Zakaria. (2023) Busting the Breast Cancer with AstraZeneca’s Gefitinib. Advances in Pharmacological and Pharmaceutical Sciences 2023, pages 1-26.
Crossref
Crossref
Sun Ruixin, Liu Yifan, Wu Chuanlong, Zhou Min, Luo Hong, Du Guoxiu, Liu Zhengyang, Sun Yansha, Dong Yiwei, Su Jingwen, Fan Mingliang, Shi Bizhi, Jiang Hua & Li Zonghai. (2023) Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer. Biochemical Pharmacology, pages 115536.
Crossref
Crossref
Xiyin Li, Lina Zhao, Ceshi Chen, Jianyun Nie & Baowei Jiao. (2022) Can EGFR be a therapeutic target in breast cancer?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188789.
Crossref
Crossref
Linda S. Steelman, William H. Chappell, Shaw M. Akula, Stephen L. Abrams, Lucio Cocco, Lucia Manzoli, Stefano Ratti, Alberto M. Martelli, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido & James A. McCubrey. (2020) Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Advances in Biological Regulation 78, pages 100758.
Crossref
Crossref
Ruixin Sun, Hong Luo, Jingwen Su, Shengmeng Di, Min Zhou, Bizhi Shi, Yansha Sun, Guoxiu Du, Honghong Zhang, Hua Jiang & Zonghai Li. (2020) Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Molecular Therapy.
Crossref
Crossref
Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian & Zhinan Chen. (2019) Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Frontiers of Medicine 13:1, pages 57-68.
Crossref
Crossref
Dimitry A. Chistiakov, Ivan V. Chekhonin & Vladimir P. Chekhonin. (2017) The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. European Journal of Pharmacology 810, pages 70-82.
Crossref
Crossref
William H. Chappell, Stephen L. Abrams, Kvin Lertpiriyapong, Timothy L. Fitzgerald, Alberto M. Martelli, Lucio Cocco, Dariusz Rakus, Agnieszka Gizak, David Terrian, Linda S. Steelman & James A. McCubrey. (2016) Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells. Advances in Biological Regulation 60, pages 64-87.
Crossref
Crossref
Wen Xu, Yanyu Bi, Jiqin Zhang, Juan Kong, Hua Jiang, Mi Tian, Kesang Li, Biao Wang, Cheng Chen, Fei Song, Xiaorong Pan, Bizhi Shi, Xianming Kong, Jianren Gu, Xiumei Cai & Zonghai Li. (2015) Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12. Oncotarget 6:36, pages 38840-38853.
Crossref
Crossref
Lynsey M Whilding & John Maher. (2015) ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy 7:3, pages 229-241.
Crossref
Crossref
James A. McCubrey, Stephen L. Abrams, Timothy L. Fitzgerald, Lucio Cocco, Alberto M. Martelli, Giuseppe Montalto, Melchiorre Cervello, Aurora Scalisi, Saverio Candido, Massimo Libra & Linda S. Steelman. (2015) Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in Biological Regulation 57, pages 75-101.
Crossref
Crossref
Nicole M. Davis, Melissa Sokolosky, Kristin Stadelman, Stephen L. Abrams, Massimo Libra, Saverio Candido, Ferdinando Nicoletti, Jerry Polesel, Roberta Maestro, Antonino D’Assoro, Lyudmyla Drobot, Dariusz Rakus, Agnieszka Gizak, Piotr Laidler, Joanna Dulińska-Litewka, Joerg Basecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Giuseppe Montalto, Melchiorre Cervello, Timothy L. Fitzgerald, Zoya N. Demidenko, Alberto M. Martelli, Lucio Cocco, Linda S. Steelman & James A. McCubrey. (2014) Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 5:13, pages 4603-4650.
Crossref
Crossref
Hui K. Gan, Anna N. Cvrljevic & Terrance G. Johns. (2013) The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS Journal 280:21, pages 5350-5370.
Crossref
Crossref
Won HwangboJeong Hyeon LeeSangjeong AhnSeojin KimKyong Hwa ParkChul Hwan KimInsun Kim. (2013)
EGFR
Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
. Korean Journal of Pathology 47:2, pages 107.
Crossref
Crossref
Kwang-Yu Chang, Shan-Yin Tsai, Shang-Hung Chen, Hsiao-Hui Tsou, Chia-Jui Yen, Ko-Jiunn Liu, Hsun-Lang Fang, Hung-Chang Wu, Bin-Fay Chuang, Shao-Wen Chou, Careen K Tang, Shyun-Yeu Liu, Pei-Jung Lu, Ching-Yu Yen & Jang-Yang Chang. (2013) Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. Journal of Biomedical Science 20:1, pages 43.
Crossref
Crossref
Catherine A. Del Vecchio, Kristin C. Jensen, Ryan T. Nitta, A. Hunter Shain, Craig P. Giacomini & Albert J. Wong. (2012) Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma. Cancer Research 72:10, pages 2657-2671.
Crossref
Crossref
Massod Rahimi, Theodore A. Toth & Careen K. Tang. (2011) CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. Cancer Letters 306:1, pages 43-51.
Crossref
Crossref
Charlotte Lund Denholt, Tina Binderup, Marie-Thérése Stockhausen, Hans Skovgaard Poulsen, Mogens Spang-Thomsen, Paul Robert Hansen, Nic Gillings & Andreas Kjær. (2011) Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer. Nuclear Medicine and Biology 38:4, pages 509-515.
Crossref
Crossref
Massod Rahimi, Kai-Ling Huang & Careen K. Tang. (2010) 3,3′-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Letters 295:1, pages 59-68.
Crossref
Crossref
Massod Rahimi, Jessica George & Careen Tang. (2010) EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms. International Journal of Cancer 126:8, pages 1850-1860.
Crossref
Crossref
Yang Zhang, Hua Su, Massod Rahimi, Ryan Tochihara & Careen Tang. (2009) EGFRvIII‐induced estrogen‐independence, tamoxifen‐resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. International Journal of Cancer 125:9, pages 2021-2028.
Crossref
Crossref
Joanne E. Ayriss, Chien-Tsun Kuan, Susan T. Boulton, David A. Reardon & Darell D. Bigner. 2009. CNS Cancer. CNS Cancer
865
898
.